Collegium Pharma (COLL) Prices 5M Share Stock Offering for Proceeds of $80M

October 26, 2016 9:02 AM EDT
Get Alerts COLL Hot Sheet
Trade COLL Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced the pricing of its previously announced public offering of 5,000,000 shares of its common stock at a price to the public of $16.00 per share. In addition, Collegium has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock offered in the public offering on the same terms and conditions. The gross proceeds of this offering are expected to be $80 million, excluding underwriters’ discounts and commissions and any exercise of the underwriters’ option to purchase an additional 750,000 shares of common stock. If the underwriters’ option is exercised in full, gross proceeds will be $92 million, excluding underwriters’ discounts and commissions. The offering is expected to close on October 31, 2016, subject to customary closing conditions.

Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers. William Blair & Company, L.L.C. and Needham & Company, LLC are acting as co-lead managers and Janney Montgomery Scott LLC is acting as co-manager in this offering.

Collegium intends to use the net proceeds from this offering for the continued commercialization of Xtampza; funding research and development efforts of its other product candidates; and working capital and general corporate purposes, which may include the acquisition or licensing of product candidates, technologies, compounds, other assets or complementary businesses.

The securities described above are being offered by Collegium pursuant to an effective shelf registration statement (including a base prospectus) filed with the Securities and Exchange Commission (“SEC”). Before you invest, you should read the base prospectus in the registration statement and related prospectus supplement that Collegium has filed with the SEC for more complete information about Collegium and this offering. The prospectus supplement and accompanying base prospectus are available for free by visiting EDGAR on the SEC’s website located at Copies of the prospectus supplement and accompanying base prospectus, when available, may also be obtained by contacting: Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Ave, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924 or by email at

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Equity Offerings

Related Entities

Piper Jaffray, William Blair, Jefferies & Co, Needham & Company, Janney Montgomery Scott, Definitive Agreement

Add Your Comment